Latest & greatest articles for alopecia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on alopecia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on alopecia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for alopecia

1. Variant PADI3 in Central Centrifugal Cicatricial Alopecia. (PubMed)

Variant PADI3 in Central Centrifugal Cicatricial Alopecia. BACKGROUND: Central centrifugal cicatricial alopecia (CCCA) is the most common form of scarring alopecia among women of African ancestry. The disease is occasionally observed to affect women in families in a manner that suggests an autosomal dominant trait and usually manifests clinically after intense hair grooming. We sought to determine whether there exists a genetic basis of CCCA and, if so, what it is. METHODS: We used exome (...) sequencing in a group of women with alopecia (discovery set), compared the results with those in a public repository, and applied other filtering criteria to identify candidate genes. We then performed direct sequencing to identify disease-associated DNA variations and RNA sequencing, protein modeling, immunofluorescence staining, immunoblotting, and an enzymatic assay to evaluate the consequences of potential etiologic mutations. We used a replication set that consisted of women with CCCA to confirm

2019 NEJM

2. Alopecia

Alopecia Top results for alopecia - Trip Database or use your Google+ account Find evidence fast My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search (...) button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for alopecia The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory

2018 Trip Latest and Greatest

3. Alopecia areata

Alopecia areata Autosynthesis - Trip Database or use your Google+ account Find evidence fast My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button

2018 Trip Evidence Maps

4. Alopecia

Alopecia Autosynthesis - Trip Database or use your Google+ account Find evidence fast My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button

2018 Trip Evidence Maps

6. Androgenic alopecia

Androgenic alopecia Androgenic alopecia - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Androgenic alopecia Last reviewed: August 2018 Last updated: March 2018 Summary Also known as pattern baldness, androgenic alopecia is a genetically determined, patterned, progressive loss of hair from the scalp and occurs in both men and women. Both androgens and genetics play a role in its pathogenesis. The term androgenic (...) alopecia is best used only when referring to male-pattern hair loss, as most females likely do not share the androgenic pathway. A more appropriate term for women is female-pattern hair loss. The term pattern hair loss will be used when referring to hair loss affecting both sexes. Men present with hair thinning in the temporal areas that advances to the crown (vertex) area as the alopecia progresses. Women usually have more diffuse thinning on the crown area, and less commonly present with a male-type

2018 BMJ Best Practice

7. Quality of life in mild and severe alopecia areata patients (PubMed)

Quality of life in mild and severe alopecia areata patients 29872683 2018 11 14 2352-6475 4 2 2018 Jun International journal of women's dermatology Int J Womens Dermatol Quality of life in mild and severe alopecia areata patients. 91-94 10.1016/j.ijwd.2017.07.001 Alopecia areata is a relapsing hair disorder characterized by a sudden hairloss and has a considerable impact on patient's quality of life. The goal of this study was to determine quality of life among patients with mild and severe (...) forms of alopecia areata and compare the two groups. During one year, 176 patients (96 mild, 80 severe) were selected and asked to complete Dermatology Life Quality Index (DLQI) questionnaires. Our study revealed that the severe group was predominantly female and had higher amount of unemployment, more prolonged disease duration, unstable disease course and facial involvement. The mean DLQI scores in the severe and mild groups were 10.7 ± 7.5 and 5.4 ± 6.8, respectively which was significantly

Full Text available with Trip Pro

2017 International journal of women's dermatology

8. Brazilian Experience of the Treatment of Alopecia Universalis with the Novel Antirheumatic Therapy Tofacitinib: A Case Series (PubMed)

Brazilian Experience of the Treatment of Alopecia Universalis with the Novel Antirheumatic Therapy Tofacitinib: A Case Series 28755063 2018 11 13 2198-6576 4 2 2017 Dec Rheumatology and therapy Rheumatol Ther Brazilian Experience of the Treatment of Alopecia Universalis with the Novel Antirheumatic Therapy Tofacitinib: A Case Series. 503-508 10.1007/s40744-017-0069-z Alopecia universalis is an autoimmune disorder for which there is no known effective therapy. Tofacitinib-a novel antirheumatic (...) therapy for rheumatoid arthritis-has been shown in some reports to induce sustained hair growth in patients with alopecia universalis. Here, we review the experiences of four different rheumatologists across the country regarding four Brazilian patients with alopecia universalis who were treated with tofacitinib . Two of these four patients had idiopathic alopecia and the other two had rheumatoid arthritis; in each case, the alopecia universalis was apparently induced by etanercept. Tofacitinib should

Full Text available with Trip Pro

2017 Rheumatology and therapy

9. Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer. (PubMed)

Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer. Importance: Chemotherapy-induced alopecia is a common and distressing adverse effect. In previous studies of scalp cooling to prevent chemotherapy-induced alopecia, conclusions have been limited. Objectives: To evaluate whether use of a scalp cooling system is associated with a lower amount of hair loss among women receiving specific chemotherapy regimens for early-stage breast cancer (...) -up for 5 years. Exposures: Use of a scalp cooling system. Scalp cooling was initiated 30 minutes prior to each chemotherapy cycle, with scalp temperature maintained at 3°C (37°F) throughout chemotherapy and for 90 minutes to 120 minutes afterward. Main Outcomes and Measures: Self-estimated hair loss using the Dean scale was assessed 4 weeks after the last dose of chemotherapy by unblinded patient review of 5 photographs. A Dean scale score of 0 to 2 (≤50% hair loss) was defined as treatment

Full Text available with Trip Pro

2017 JAMA

10. Effect of a Scalp Cooling Device on Alopecia in Women Undergoing Chemotherapy for Breast Cancer: The SCALP Randomized Clinical Trial. (PubMed)

Effect of a Scalp Cooling Device on Alopecia in Women Undergoing Chemotherapy for Breast Cancer: The SCALP Randomized Clinical Trial. Importance: Chemotherapy may induce alopecia. Although scalp cooling devices have been used to prevent this alopecia, efficacy has not been assessed in a randomized clinical trial. Objectives: To assess whether a scalp cooling device is effective at reducing chemotherapy-induced alopecia and to assess adverse treatment effects. Design, Setting, and Participants (...) (n = 63). Scalp cooling was done using a scalp cooling device. Main Outcomes and Measures: The primary efficacy end points were successful hair preservation assessed using the Common Terminology Criteria for Adverse Events version 4.0 scale (grade 0 [no hair loss] or grade 1 [<50% hair loss not requiring a wig] were considered to have hair preservation) at the end of 4 cycles of chemotherapy by a clinician unaware of treatment assignment, and device safety. Secondary end points included wig

Full Text available with Trip Pro

2017 JAMA

13. Alopecia areata

Alopecia areata Alopecia areata - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Alopecia areata Last reviewed: August 2018 Last updated: November 2017 Summary Autoimmune disease that targets the hair follicle. Characterised by sudden onset of patchy hair loss. Diagnosis is clinical. Characteristic physical findings are exclamation mark hairs (short, broken hairs) and a positive pull test. A scalp biopsy shows (...) perifollicular inflammation. Topical or intralesional corticosteroids are appropriate for patients with limited hair loss. Skin atrophy can be a temporary side effect. Definition Alopecia areata (AA) is an autoimmune disease that affects almost 2% of the population in the US. Safavi KH, Muller SA, Suman VJ, et al. Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989. Mayo Clin Proc. 1995;70:628-633. http://www.ncbi.nlm.nih.gov/pubmed/7791384?tool=bestpractice.com Inflammatory cells

2017 BMJ Best Practice

14. Risk of erectile dysfunction associated with use of 5-α reductase inhibitors for benign prostatic hyperplasia or alopecia: population based studies using the Clinical Practice Research Datalink. (PubMed)

Risk of erectile dysfunction associated with use of 5-α reductase inhibitors for benign prostatic hyperplasia or alopecia: population based studies using the Clinical Practice Research Datalink. OBJECTIVE: To estimate the risk of erectile dysfunction in men who used 5-α reductase inhibitors to treat benign prostatic hyperplasia or alopecia. DESIGN: Cohort studies with nested case-control analyses. SETTING: UK Clinical Practice Research Datalink. POPULATION: Two populations of men free of risk (...) factors for erectile dysfunction and other sexual dysfunction or its treatment: men aged 40 or more with benign prostatic hyperplasia who received a prescription for a 5-α reductase inhibitor (finasteride or dutasteride) or α blocker, or both, and men aged 18-59 with alopecia. EXPOSURES: In the benign prostatic hyperplasia study, exposures were classified as 5-α reductase inhibitors only, 5-α reductase inhibitors+α blockers, or α blockers only. In the alopecia study, exposures were finasteride 1 mg

Full Text available with Trip Pro

2016 BMJ

15. Naltrexone for Alopecia: Clinical Effectiveness

Naltrexone for Alopecia: Clinical Effectiveness Naltrexone for Alopecia: Clinical Effectiveness | CADTH.ca Find the information you need Naltrexone for Alopecia: Clinical Effectiveness Naltrexone for Alopecia: Clinical Effectiveness Published on: August 8, 2016 Project Number: RA0859-000 Product Line: Research Type: Drug Report Type: Reference List Result type: Report Question What is the clinical effectiveness of naltrexone for the treatment of alopecia? Key Message No literature (...) was identified regarding the clinical effectiveness of naltrexone for the treatment of alopecia. Tags alopecia, hair, naltrexone, other miscellaneous topics, hair loss, hairloss Files Rapid Response Reference List Published : August 8, 2016 Follow us: © 2017 Canadian Agency for Drugs and Technologies in Health Get our newsletter:

2016 Canadian Agency for Drugs and Technologies in Health - Rapid Review

16. Alopecia in survivors of critical illness (PubMed)

Alopecia in survivors of critical illness 28979506 2018 11 13 1751-1437 17 3 2016 Aug Journal of the Intensive Care Society J Intensive Care Soc Alopecia in survivors of critical illness. 270 10.1177/1751143715626165 Battle Ceri E CE Critical Care Unit, Morriston Hospital, Swansea, UK. James Karen K Critical Care Unit, Morriston Hospital, Swansea, UK. Temblett Paul P Critical Care Unit, Morriston Hospital, Swansea, UK. eng Journal Article 2016 07 25 England J Intensive Care Soc 101538668 1751

Full Text available with Trip Pro

2016 Journal of the Intensive Care Society

17. Alopecia, androgenetic - female

Alopecia, androgenetic - female Alopecia, androgenetic - female - NICE CKS Clinical Knowledge Summaries Share Alopecia, androgenetic - female - Summary Androgenetic alopecia (or female pattern hair loss) describes a distinctive pattern of hair loss, which may occur in genetically predisposed women and is thought to be androgen dependent. Hair loss is usually diffuse and affects the top of the scalp. The underlying pathological process involves pigmented terminal hairs gradually being replaced (...) by smaller, less pigmented hairs similar to vellus hairs. The prevalence and severity of androgenetic alopecia in women increases greatly after the menopause and affects about a third of white women aged 70 years and older. Complications of androgenetic alopecia may include adverse psychosocial effects. Hair loss in women tends to progress over time, but the rate of progression is unpredictable. Women with androgenetic alopecia rarely go completely bald. The diagnosis is usually made from the history

2016 NICE Clinical Knowledge Summaries

18. Alopecia, androgenetic - male

Alopecia, androgenetic - male Alopecia, androgenetic - male - NICE CKS Clinical Knowledge Summaries Share Alopecia, androgenetic - male: Summary Androgenetic alopecia describes a distinctive pattern of hair loss, which may occur in genetically predisposed men and is thought to be androgen dependent. In men, hair loss usually initially involves the front and sides of the scalp and progresses towards the back of the head. The underlying pathological process involves pigmented terminal hairs (...) gradually being replaced by smaller, less pigmented hairs similar to vellus hairs. Male androgenetic alopecia is thought to be a polygenic disorder. It is thought that in genetically predisposed hair follicles there are increased numbers of androgen receptors and/or increased activity of 5-alpha reductase, an enzyme which mediates the effects of androgens on scalp hair. The prevalence and the severity of androgenetic alopecia is highest in white men, tends to occur less in black men, and later and more

2016 NICE Clinical Knowledge Summaries

19. Hair micro transplant using follicular unit extraction technique for alopecia

Hair micro transplant using follicular unit extraction technique for alopecia Hair micro transplant using follicular unit extraction technique for alopecia Hair micro transplant using follicular unit extraction technique for alopecia Macchiavello D, Bardach A, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Ciapponi A, López A, Rey-Ares L., Hernandez Vásquez A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA (...) . No evaluation of the quality of this assessment has been made for the HTA database. Citation Macchiavello D, Bardach A, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Ciapponi A, López A, Rey-Ares L., Hernandez Vásquez A. Hair micro transplant using follicular unit extraction technique for alopecia. Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Documentos de Evaluación de Tecnologías Sanitarias, Informe de Respuesta Rápida N° 444, Buenos Aires, Argentina

2015 Health Technology Assessment (HTA) Database.

20. Testing Vitamin B12 Levels in Neuropathy, Alopecia, Dizziness, and Fatigue: A Rapid Review

Testing Vitamin B12 Levels in Neuropathy, Alopecia, Dizziness, and Fatigue: A Rapid Review Testing vitamin B12 levels in neuropathy, alopecia, dizziness, and fatigue: a rapid review Testing vitamin B12 levels in neuropathy, alopecia, dizziness, and fatigue: a rapid review Health Quality Ontario Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation Health Quality Ontario. Testing vitamin B12 levels in neuropathy, alopecia, dizziness, and fatigue: a rapid review. Toronto: Health Quality Ontario (HQO). Rapid Review. 2014 Authors' objectives The objective of this analysis is to identify the clinical utility of testing vitamin B12 levels in cases of neuropathy, alopecia, dizziness, and fatigue. Authors' conclusions There is very low quality evidence that there is no association between vitamin B12 levels and neuropathy. There is very low

2014 Health Technology Assessment (HTA) Database.